Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion ...

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli ...

Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design ...

Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

U.S. Secretary of Commerce Howard Lutnick said Lilly was doing "exactly what the President was hoping would happen." ...

(AMZN), Eli Lilly and Co. (LLY) and S&P Global Inc. (SPGI), as well as a micro-cap stock CVD Equipment Corporation (CVV). Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound ...

Eli Lilly LLY1.46%increase; green up pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound. The Indiana-based drugmaker is slashing the prices of its 2.5 mg ...